85.6% effective against UK epidemic mutant virus
–
NovaVax announced on the 28th (local time) that the novel coronavirus infection (Corona 19) vaccine developed by the US pharmaceutical company NovaVax showed 89.3% effectiveness in clinical trials.
According to foreign media such as Reuters, NovaVax announced that the results of a preliminary investigation showed 89.3% of the preventive effect in a phase 3 clinical trial conducted in the UK on 15,000 people aged 18 to 84.
About 27% of participants in the UK phase 3 clinical trial were over 65 years old.
The vaccine developed by NovaVax showed 85.6% of the prevention effect against the Corona 19 mutant virus that is currently prevalent in the UK, NovaVax said.
/yunhap news
–
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
–
